FDA OTC Labeling Final Rule Based On "Unrealistic Assumptions" - CHPA
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule on OTC labeling "appears to be based on unrealistic assumptions," Consumer Healthcare Products Association Senior VP and Director of Science & Technology William Soller, PhD, asserted at an FDA "feedback" meeting April 23. "A number of examples used by FDA" as samples of OTC labels "are unrealistic projections of actual labeling," Soller added.
You may also be interested in...
OTC Label Multiple Columns Suggested For Elongated Packaging By CHPA
FDA should allow the use of more than two columns to present required information on OTC labeling for products with long rectangular packaging, Consumer Healthcare Products Association Senior VP and Director of Science & Technology William Soller, PhD, said at a "feedback" meeting on the OTC labeling final rule in Rockville, Md. June 29.
Trade Dress Uniqueness Restricted By OTC Labeling Rule, CTFA Argues
FDA's OTC labeling final rule limits the number of options companies have to distinguish their products on retail shelves, Cosmetic, Toiletry & Fragrance Association VP-Legal & General Counsel Thomas Donegan maintained during a "feedback" meeting with the agency in Rockville, Md. June 29.
OTC Label Multiple Columns Suggested For Elongated Packaging By CHPA
FDA should allow the use of more than two columns to present required information on OTC labeling for products with long rectangular packaging, Consumer Healthcare Products Association Senior VP and Director of Science & Technology William Soller, PhD, said at a "feedback" meeting on the OTC labeling final rule in Rockville, Md. June 29.